Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

Post by: Geert in Immunic Press Release
NEW YORK, Sept. 30, 2021…
read more
01 Oct 2021
0

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Post by: Geert in Immunic Press Release
Immunic and the University Medical…
read more
22 Sep 2021
0

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Closing of…
read more
20 Jul 2021
0

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces FDA Clearance…
read more
01 Jul 2021
0

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Post by: Geert in Immunic Press Release
Immunic and 4SC AG Sign…
read more
01 Apr 2021
0

Immunic, Inc. Announces Positive Top-Line Data From Investigator- Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces Positive Top-Line…
read more
18 Feb 2021
0

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces That Oral…
read more
18 Feb 2021
0

Immunic, Inc. Added to NASDAQ Biotechnology Index

Post by: Geert in Immunic Press Release
Immunic, Inc. Added to NASDAQ…
read more
14 Dec 2020
0

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Post by: Geert in Immunic Press Release
Immunic, Inc. Announces 200 Patients…
read more
02 Nov 2020
0

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

Post by: Geert in Immunic Press Release
EIB Provides Immunic With up…
read more
21 Oct 2020
0